The company said it will use part of the proceeds to repurchase some of its senior notes due in January 2025, and the rest for corporate purposes.
The firm will use the funds to continue its commercialization plans for the Unyvero diagnostic test cartridges and instruments.
Funds raised through the offering will be used to buy back shares of common stock from shareholders in privately negotiated transactions.
Initial purchasers will also have a 30-day option to purchase up to an addition $100 million of the notes for a potential offering size of $750 million.
The company said it plans to use the net proceeds for general corporate purposes, including for working capital and possible acquisitions.
The firm has made two separate senior notes offerings in euros and British pounds, and it plans to use the proceeds to redeem other outstanding notes.
The company plans to use the proceeds to repay loan and revolving credit facilities incurred to pay a portion of its 2017 acquisition of Euroimmun.
The firm has said that it intends to use the net proceeds and available cash to redeem its outstanding 5.25 percent senior notes due in 2022 in the amount of $1 billion.
Underwriter Merrill Lynch exercised in full the option to purchase up to an additional $90M in senior notes on top of a $600M notes offering announced last week.
The firm intends to use the net proceeds and available cash to redeem its outstanding 5.25 percent senior notes due 2022 in the amount of $1 billion.
The long-running Framingham Heart Study has received a $38 million grant, according to the Boston Globe.
A Stanford University investigation finds that its researchers did not take part in He Jiankui's work to develop gene-edited infants.
Retraction Watch reports that two researchers had both a Science and a Nature paper retracted last week.
In Genome Biology this week: genomic sequencing of milkweed bug, benchmark comparison of single-cell RNA sequencing platforms, and more.